anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: There is an increasing interest in the use of intra-articular (IA) antibiotic infusion as a stand-alone or adjuvant therapy to standard revision surgery for periprosthetic joint infection (PJI). The objective of this systematic review is to evaluate the evidence with respect to this up-and-coming treatment modality.
METHODS: A systematic review of studies published until April 2023 was conducted using PubMed, Embase, MEDLINE and Cochrane databases. Quality assessment was performed with the National Institute of Health quality assessment tool. Inclusion criteria were adult patients (≥ 18 years) with a mean follow-up of ≥ 11 months and a score ≥ 6 on the National Institute of Health quality assessment tool. Primary outcome was eradication of infection.
RESULTS: 15 articles, encompassing 631 PJIs in 626 patients, were included in the final analysis, all level IV case series. The majority was treated with single-stage revision with adjuvant IA antibiotic infusion (79.1%). The remaining PJIs were treated with stand-alone IA antibiotic infusion (12.2%), DAIR (debridement, antibiotics and implant retention) with adjuvant IA antibiotic infusion (5.7%) or two-stage revision with adjuvant IA antibiotic infusion (3.0%). Mean duration of IA antibiotic infusion was 19 days (range 3-50). An overall failure rate of approximately 11% was found. In total 117 complications occurred, 71 were non-catheter-related and 46 were catheter-related. The most common catheter-related complications were premature loss of the catheter (18/46) and elevated blood urea nitrogen (BUN) and creatinine levels (12/46).
CONCLUSIONS: Due to the lack of comparative studies the (added) benefit of IA antibiotic infusion in the treatment of PJI remains uncertain. Based on the current evidence, we would advise against using it as a stand-alone treatment. A prospective randomized controlled trial using a well-described infusion protocol is needed to see if the potential benefits justify the increased costs and potential complications of this treatment modality.
PURPOSE: Evidence suggests that MAPK pathway activation, as measured by ERK1/2 phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent glioblastoma receiving anti-PD-1 therapy. We aimed to validate these findings in independent cohorts.
EXPERIMENTAL DESIGN: In a 24-patient clinical trial on recurrent glioblastoma and high-grade gliomas, we examined the link between p-ERK levels and OS. Patients received intravenous nivolumab, followed by maximal safe resection and an intracerebral injection of either ipilimumab alone or combined with nivolumab. Biweekly adjuvant nivolumab was then administered up to five times (NCT03233152). Using REporting recommendations for tumor MARKER prognostic studies (REMARK) criteria, we conducted independent analyses for p-ERK quantification and statistical evaluations. Additional comparative analysis included prior cohorts, totaling 65 patients. Cox proportional hazards models and meta-analysis were employed to assess p-ERK as a predictive biomarker after immunotherapy.
RESULTS: Lower median p-ERK+ cell density was observed compared with prior studies, likely due to variable tissue processing across cohorts. Nonetheless, high p-ERK was associated with prolonged OS, particularly in isocitrate dehydrogenase wild-type glioblastomas (P = 0.036). Median OS for high and low p-ERK patients were 55.6 and 30 weeks, respectively. Multivariable analysis reinforced p-ERK's significance in survival prediction (P = 0.011). Upon p-ERK normalization across cohorts (n = 65), meta-analysis supported the survival benefit of elevated tumor p-ERK levels (P = 0.0424).
CONCLUSIONS: This study strengthens the role of p-ERK as a predictive biomarker for OS in patients with glioblastoma on immune checkpoint blockade. Future research should focus on further validation in prospective trials and the standardization of preanalytical variables influencing p-ERK quantification.
World Health Organization, defines intimate partner violence as behaviours that cause physical, sexual or psychological harm in an intimate relationship. These behaviours include physical aggression, sexual coercion, psychological abuse and controlling behaviours. One in three women will experience violence from a partner at some point in their lifetime. A strong correlation has been identified between women's exposure to violence and their susceptibility to mental health issues. In instances of prolonged violence, women tend to exhibit a range of emotional responses, including feelings of insecurity, loss of control, guilt, low self-esteem, helplessness, and hopelessness.

Interpersonal Psychotherapy (IPT) is a time-limited psychotherapy developed in the 1970s for the treatment of depression. It focuses on interpersonal relationships and social support systems. The primary focus of IPT is on the resolution of existing interpersonal conflicts. IPT is delivered to different clinical populations across the lifespan in a range of flexible formats, including individual, couple, group, telephone sessions, and web-based applications in a variety of settings and doses. It has been demonstrated to be an efficacious intervention for the treatment of psychiatric disorders, including anxiety disorders, depression, post-traumatic stress disorder, and bipolar disorder, particularly during the perinatal period. Despite the existence of numerous studies examining the impact of IPT across diverse populations, only one investigation has explored the efficacy of IPT in women who have experienced violence. In the aforementioned examination, no established treatment program for women victims of intimate partner violence has been identified in our country. Although intimate partner violence affects a significant proportion of the population, the paucity of studies focusing on interpersonal relationships in this context represents a gap in the existing literature.

Given the high prevalence of violence against women and the associated burden of physical, mental, social, and social problems, as well as the limitations of existing intervention programs designed to enhance the psychosocial well-being of women victims of intimate partner violence, it is imperative to develop novel intervention strategies that prioritize interpersonal relationships and aim to bolster the coping skills and social support systems of these individuals. In light of the aforementioned considerations, the objective of the present study is to examine the impact of an intervention program based on interpersonal relationship psychotherapy on the psychosocial well-being of women victims of intimate partner violence. This study will examine the psychosocial well-being, interpersonal problems and mental well-being levels of women victims of intimate partner violence.
PURPOSE:To examine and diagnose a cell, body fluid, etc., by forming a complex with an antigen derived from Candida albicans, etc. CONSTITUTION:A bacterium cell obtained by culturing Candida albicans, Candida tropicalis and Candida guillier mondii is subjected to mechanical breakage to afford an antigen liquid (A). Then BALB/C mouse, etc., is immunized with the liquid A and spleen is delivered from the immunized mouse to provide an immunized spleen cell (B). Then the cell B is blended with a mouse myeloma cell (C) such as P3U1 at a ratio of cell number of the ingredient C: the ingredient B of 1:1-10 and the blend is fused with electric fusion method, etc., to provide the hybridoma (D). Then the ingredient D is subjected to screening using an enzyme immune measuring method, etc. and then cultured with NS-1 culture medium containing glutamine, etc., to provide the cultured mixture (E). Then the ingredient E is extracted and separated to provide the aimed monoclonal antibody.
INTRODUCTION: The "Programme d'Accompagnement du retour à Domicile" (PRADO) COPD is a home discharge support program dedicated to organizing care pathways following hospitalization for COPD exacerbation. This study aimed at assessing its medico-economic impact.
METHODS: This was a retrospective database study of patients included in the PRADO BPCO between 2017 and 2019. Data were extracted from the National Health Data System. A control group was built using propensity score matching. Morbi-mortality and costs (national health insurance perspective) were measured during the year following hospitalization.
RESULTS: While the proportion of patients with a care pathway complying with recommendations from the National Health Authority was higher in the PRADO group, there was no significant effect on mortality and 12-month rehospitalization. In the PRADO group, the rehospitalization rate was lower when the care pathway was optimal. Healthcare costs per patient were 670 € higher in the PRADO group.
CONCLUSIONS: The PRADO COPD improves quality of care but without decreasing rehospitalizations and mortality, although rehospitalizations did decrease among PRADO group patients benefiting from an optimal care pathway.
Currently, a prognostic biomarker-based model is being developed to predict the onset and disease progression of Huntington's Disease (HD) and Spinocerebellar Ataxia (SCA) types 1 and 3, both late-onset genetic neurodegenerative diseases lacking a disease-modifying treatment (DMT). The need for more accurate predictions of onset and disease progression arises in the context of clinical trials evaluating the effectiveness of potential DMTs and identifying the optimal time to initiate such a DMT. Moreover, such a prognostic model may provide mutation carriers with personal utility. The aim of this article is to anticipate the ethical issues raised by these new prognostic models and to formulate the ethical issues that need to be addressed to facilitate an ethically responsible development and implementation of such a model. Part one of this article describes the ethical issues raised by presymptomatic genetic testing for HD and evaluates whether and how these issues may also occur by predicting onset and disease progression. Part two presents the results of a critical interpretative review into the ethical issues raised by biomarker testing in other late-onset neurodegenerative diseases lacking a DMT. The review aims to identify new ethical issues related to biomarker testing for predicting the onset and disease progression of HD and SCA. Finally, based on parts one and two, part three proposes a research agenda for the near future regarding the most pressing ethical issues that need to be addressed to ensure an ethically responsible implementation of such a prognostic model in both research settings and clinical practice.
The invention provides a composition for skin, which includes an aqueous phase and oil particles dispersed in the aqueous phase. The viscosity of the composition for skin is around 1000 to 100000mPa.s in room temperature. The composition for skin is characterized in that the average diameter of the oil particles is around 0.1 to 2 mm and contains 15 to 60 mass percentage of ceramide. The mass percentage of the oil phase particles in the composition for skin is around 0.5 to 15 percents. The aqueous phase includes 0.1 to 10 mass percentages of polymer. The invention also relates to a manufacturing method of the composition for skin, which is characterized in that adding a solved oil phase to an upper portion of an aqueous phase heated to a predetermined temperature or adding the aqueous phase heated to the predetermined temperature to an upper portion of the oil phase, and stirring the aqueous phase and oil phase, while cooling to room temperature to obtain the oil phase particles.
BACKGROUND: Bufalin (BA) is a potent traditional Chinese medicine derived from toad venom. It has shown significant antitumor activity, but its use is limited by cardiotoxicity, which necessitates innovative delivery methods, such as rod-shaped mesoporous silica nanoparticles (rMSNs). rMSNs have been extensively employed for reducing drug toxicity and for controlled or targeted drug delivery in tumor therapy. However, their potential in delivering BA has not been completely elucidated. Therefore, in this study, BA-loaded rMSNs (BA-rMSNs) were developed to investigate their potential and mechanism in impairing colon cancer cells.
METHODS: rMSNs were developed via the sol‒gel method. Drug encapsulation efficiency and loading capacity were determined to investigate the advantages of the rMSN in loading BA. The antiproliferative activities of the BA-rMSNs were investigated via 5-ethynyl-2'-deoxyuridine and CCK-8. To evaluate cell death, Annexin V-APC/PI apoptotic and calcein-AM/PI double staining were performed. Western blotting, oil red O staining, and Nile red solution were employed to determine the ability of BA-rMSNs to regulate lipophagy.
RESULTS: The diameter of the BA-rMSNs was approximately 60 nm. In vitro studies demonstrated that BA-rMSNs markedly inhibited HCT 116 and HT-29 cell proliferation and induced cell death. In vivo studies revealed that BA-rMSNs reduced BA-mediated cardiotoxicity and enhanced BA tumor targeting. Mechanistic studies revealed that BA-rMSNs blocked lipophagy.
CONCLUSIONS: rMSNs reduced BA-mediated cardiotoxicity and impaired the growth of colon cancer cells. Mechanistically, antitumor activity depends on lipophagy.
PURPOSE: A cosmetic composition containing mixing extract comprised of Siberian chrysanthemum and aronia melanocarpa is provided to have antibacterial activity on gram negative bacteria, gram positive bacteria, yeast and mold and improve embalming ability through broad antimicrobial spectrum without affecting stability of formulation. CONSTITUTION: A cosmetic composition includes mixing extract comprised of siberian chrysanthemum and aronia melanocarpa as an active ingredient. The mixing extract is mixed with extract of siberian chrysanthemum and extract of aronia melanocarpa at a volume ratio of 1:1. The extract of siberian chrysanthemum is manufactured by mixing distilled water and extracted siberian chrysanthemum. The extract of aronia melanocarpa is manufactured by mixing extracted aronia melanocarpa and at least one solvent selected from a group consisting of water, lower alcohol of C1-C4, glycerol, propylene glycol, 1,3-butylene glycol, ethyl acetate, benzene, hexane, diethylether and dichloromethane. In the extraction of the aronia melanocarpa, methanol or mixture of methanol and water is used as an extraction solvent.
In one embodiment, the present invention is directed to a gaming device. The gaming device may include a random number generator (83). A skill game device may also be included. The skill game device is configured to allow a game player to play a skill game having a skill game outcome. The skill game outcome is influenced by the skill of the game player and the skill game outcome may be displayed to the player. The gaming device may also include a processor (85) in communication with the random number generator. The processor may be configured to randomly determine a prize and to calculate a multiplier (84) that may be the quotient of the prize divided by the skill game outcome. The gaming device may also include a display (54, 56) in communication with the processor and the skill game device. The display may be adapted to show both the prize and the multiplier.
Maternal malnutrition can alter developmental biology, programming health and disease in offspring. The increase in sugar consumption during the peripubertal period, a worldwide concern, also affects health through adulthood. Studies have shown that maternal exposure to a low protein diet (LPD) is associated with an increase in prostate disease with aging. However, the combined effects of maternal LPD and early postnatal sugar consumption on offspring prostate disorders were not investigated. The effects on aging were evaluated using a maternal gestational model with lactational LPD (6% protein) and sugar consumption (10%) from postnatal day (PND) 21-90, associating the consequences on ventral prostate (VP) rats morphophysiology on PND540. An increase was shown in mast cells and in the VP of the CTR + SUG and Gestational and Lactational Low Protein (GLLP) groups. In GLLP + SUG, a significant increase was shown in TGF-β1 expression in both the systemic and intra-prostatic forms, and SMAD2/3p had increased. The study identified maternal LPD and sugar consumption as risk factors for prostatic homeostasis in senility, activating the TGFβ1-SMAD2/3 pathway, a signaling pathway with potential markers for prostatic disorders.
Swallow JADENU tablets once daily with water or other liquids, preferably at the same time each day. Take JADENU tablets on an empty stomach or with a light meal (contains less than 7% fat content and approximately 250 calories). Examples of light meals include 1 whole wheat English muffin, 1 packet jelly (0.5 ounces), and skim milk (8 fluid ounces) or a turkey sandwich (2 oz. turkey on whole wheat bread w/ lettuce, tomato, and 1 packet mustard). Do not take JADENU tablets with aluminum-containing antacid products [see Drug Interactions (7.1)]. For patients who have difficulty swallowing whole tablets, JADENU tablets may be crushed and mixed with soft foods (e.g., yogurt or applesauce) immediately prior to use and administered orally. Commercial crushers with serrated surfaces should be avoided for crushing a single 90 mg tablet. The dose should be immediately and completely consumed and not stored for future use. 

Take JADENU Sprinkle granules on an empty stomach or with a light meal [see Clinical Pharmacology (12.3)]. Administer JADENU Sprinkle granules by sprinkling the full dose on soft food (e.g., yogurt or applesauce) immediately prior to use and administered orally. JADENU Sprinkle granules should be taken once a day, preferably at the same time each day. Do not take JADENU Sprinkle granules with aluminum-containing antacid products [see Drug Interactions (7.1)]. 

For patients who are currently on chelation therapy with Exjade tablets for oral suspension and converting to JADENU, the dose should be about 30% lower, rounded to the nearest whole tablet or nearest whole sachet content for granules. The table below provides additional information on dosing conversion to JADENU.
Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.
The Zingiber zerumbet rhizomes are traditionally used to treat fever, and the in vitro inhibitory effect of ethyl acetate extract from Zingiber zerumbet rhizomes (EAEZZR) against DENV2 NS2B/NS3 (two non-structural proteins, NS2 and NS3 of dengue virus type 2) has been reported earlier. This study was carried out to establish an acute toxicity profile and evaluate the anti-fever (anti-pyretic) activities of EAEZZR in yeast-induced fever in rats. The major compound of EAEZZR, zerumbone, was isolated using chromatographic methods including column chromatography (CC) and preparative thin-layer chromatography (PTLC). Additionally, the structure of zerumbone was elucidated using nuclear magnetic resonance (NMR), liquid chromatography mass spectrometer-ion trap-time of flight (LCMS-IT-TOF), infrared (IR), and ultraviolet (UV) spectroscopy. The toxicity of EAEZZR was evaluated using Organization for Economic Cooperation and Development Test Guideline 425 (OECD tg-425) with minor modifications at concentrations EAEZZR of 2000 mg/kg, 3000 mg/kg, and 5000 mg/kg. Anti-fever effect was determined by yeast-induced fever (pyrexia) in rats. The acute toxicity study showed that EAEZZR is safe at the highest 5000 mg/kg body weight dose in Sprague Dawley rats. Rats treated with EAEZZR at doses of 125, 250, and 500 mg/kg exhibited a significant reduction in rectal temperature (TR) in the first 1 h. EAEZZR at the lower dose of 125 mg/kg showed substantial potency against yeast-induced fever for up to 2 h compared to 0 h in controls. A significant reduction of TR was observed in rats treated with standard drug aspirin in the third through fourth hours. Based on the present findings, ethyl acetate extract of Zingiber zerumbet rhizomes could be considered safe up to the dose of 5000 mg/kg, and the identification of active ingredients of Zingiber zerumbet rhizomes may allow their use in the treatment of fever with dengue virus infection.
Treatment strategies for treatment-resistant depression (TRD) involve either switching to another antidepressant, augmenting the first-line treatment with various pharmacologic agents, or switching to a different medication in combination with another agent. This study includes 2 phases: an open-label treatment phase and a double-blind maintenance phase, during which neither the patient nor the physician knows whether risperidone or placebo is administered. The open-label phase has an initial period of 6 weeks during which patients with TRD receive only citalopram, a selective serotonin reuptake inhibitor (SSRI). Risperidone is then added to the treatment regimen for 4 weeks to evaluate its short-term effect in augmenting the therapy. The double-blind phase last for 6 months and evaluates the relapse prevention of continued risperidone augmentation therapy compared with placebo augmentation of the SSRI. Targeted daily doses of citalopram and risperidone are adjusted for younger adults (18 to 54 years of age) and older adults (55 to 85 years of age). Assessments of effectiveness include the Montgomery-Asberg Depression Rating Scale (MADRS); Hamilton Rating Scale of Depression (HAM-D); Clinical Global Impression of Severity (CGI-S); response rate, determined by the proportion of patients showing \>=50% improvement on MADRS total score; and relapse, evaluated by changes in CGI or HAM-D scores. Safety evaluations include the incidence of adverse events throughout the study, vital signs (pulse and blood pressure) and weight, and clinical laboratory tests (hematology, biochemistry, urinalysis) at specified intervals. The study hypothesis is that risperidone augmentation of SSRI therapy will show significant improvement in symptoms of depression compared with SSRI monotherapy and that risperidone augmentation will show better time-to-relapse than placebo augmentation in patients with TRD. Once daily, oral tablets of risperidone (0.25 milligram\[mg\], 0.5mg, 1.0mg, and 2.0mg), citalopram (20mg and 40mg) or placebo. Risperidone for 30 weeks; 0.25-2.0mg for younger adults, 0.25-1.0mg for older adults. Citalopram for 36 weeks; 20-60 mg for younger adults; 20-40 mg for older adults.
An 8-week interview will be conducted with the individuals in the experimental group in the research in which the mindfulness training psychiatric nursing approach is applied. The control group will continue their routine school life. Individuals in the experimental group will be trained as a group and initiatives will be implemented in line with the goals of the individuals and the objectives of the research.